Login to Your Account

Termination Resolves Litigation

Amylin, Lilly Break Up; New Suitor Waiting in the Wings?

By Jennifer Boggs
Managing Editor

Wednesday, November 9, 2011
Amylin Pharmaceuticals Inc. and Eli Lilly and Co. are calling it quits after a nearly decade-long collaboration on diabetes drug exenatide, a move that leaves Amylin positioned as a potentially hot takeover candidate, especially if the once-weekly version of the glucagon-like peptide-1 receptor agonist, Bydureon, finally clears FDA hurdles early next year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription